1. OC.06.4: The Addition of an Immunosuppressant is an Effective Optimization Strategy after Loss of Response to Anti-Tnf Alpha Monotherapy in Patients with Inflammatory Bowel Disease: A Two-Year Experience. (15th March 2017) Authors: Macaluso, F.S.; Sapienza, C.; Ventimiglia, M.; Renna, S.; Rizzuto, G.; Orlando, R.; Affronti, M.; Orlando, E.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC.06.5: Mycophenolate Mofetil is a Valid Option in Patients with Inflammatory Bowel Disease Resistant to TNF-Alpha Inhibitors and Conventional Immunosuppressants. (15th March 2017) Authors: Macaluso, F.S.; Maida, M.; Renna, S.; Orlando, E.; Affronti, M.; Sapienza, C.; Dimarco, M.; Orlando, R.; Rizzuto, G.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P.11.3: Poor Tolerability Profile of Thiopurines in Inflammatory Bowel Disease: A Prospective Single-Centre Experience. (15th March 2017) Authors: Macaluso, F.S.; Maida, M.; Renna, S.; Dimarco, M.; Sapienza, C.; Affronti, M.; Orlando, E.; Rizzuto, G.; Orlando, R.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗